oral, BP, selective OX1R GPCR antagonist

orally efficacious in panic attack models

from optimization of internal OX2R antagonist

ACS Med. Chem. Lett., May 5, 2020

Janssen R&D, San Diego, CA


JNJ-54717793 is a selective antagonist of the orexin-1 receptor intended for use in anxiety disorders, in contrast to dual orexin-1/2 inhibitors and orexin-2 inhibitors typically applied for sleep disorders. It’s…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: